Internal Reference Number: FOI_7654
Date Request Received: 08/01/2024 00:00:00
Date Request Replied To: 12/02/2024 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products Rheumatology
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara | |
| Answer To Question 1: • Abatacept [Orencia] 57 • Adalimumab [Humira] 24 • Adalimumab Biosimilars 342 • Apremilast [Otezla] 11 • Baricitinib [Olumiant] 66 • Bimekizumab [Bimzelx] 0 • Certolizumab [Cimzia] 42 • Etanercept [Enbrel] 12 • Etanercept Biosimilars 149 • Filgotinib [Jyseleca] 27 • Golimumab [Simponi] 21 • Guselkumab [Tremfya] 14 • Infliximab [Remicade] 8 • Infliximab Biosimilars 28 • Ixekizumab [Taltz] 44 • Risankizumab [Skyrizi] 0 • Rituximab [MabThera] 7 • Rituximab Biosimilars 97 • Sarilumab [Kevzara] <5 • Secukinumab [Cosentyx] 20 • Tocilizumab [Ro Actemra] 49 • Tocilizumab Biosimilars 0 • Tofacitinib [Xeljanz] 21 • Upadacitinib [Rinvoq] 62 • Ustekinumab [Stelara 10 | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] 9 • Adalimumab Biosimilars 50 • Certolizumab [Cimzia] 10 • Etanercept [Enbrel] <5 • Etanercept Biosimilars 24 • Golimumab [Simponi] 9 • Infliximab [Remicade] <5 • Infliximab Biosimilars 6 • Ixekizumab [Taltz] <5 • Secukinumab [Cosentyx] 9 • Tofacitinib [Xeljanz] 21 • Upadacitinib [Rinvoq] 7 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
